FIELD: medicine.
SUBSTANCE: present invention ensures a new composition of CTLA-4 antibodies and its versions, containing a chelating agent. The composition contains at least one antibody specifically binding human CTLA-4 with heavy and easy chains with amino acid sequence (AS) at least 90% identical to related sequences of common antibody, particularly Ticilimumab (AS specified in the description). The composition contains EDTA as a chelating agent, and also may contain at least buffer, histidine, surface-active substance, isotonic agent, e.g., Polysorbate 80, trehalose in various combinations and ratios. The composition is characterised with improved properties of antibody aggregation, fragmentation, freezing/thawing instability, discolouration and/or deamidation.
EFFECT: composition can be used for treatment of neoplasm-associated diseases and conditions.
22 cl, 14 dwg, 37 tbl, 15 ex
| Title | Year | Author | Number |
|---|---|---|---|
| STABLE AQUEOUS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) ANTIBODY COMPOSITION | 2016 |
|
RU2699544C2 |
| STABLE LIQUID PREPARATION OF ANTIBODY | 2009 |
|
RU2518278C2 |
| STABLE PHARMACEUTICAL PREPARATION BASED ON THE PD-1 ANTIBODY AND ITS USE IN MEDICINE | 2016 |
|
RU2731418C2 |
| MOLECULES WHICH BIND TO 4-1BB | 2011 |
|
RU2710717C2 |
| COMPOSITIONS OF ANTI-PD-1 ANTIBODIES | 2019 |
|
RU2772781C2 |
| CHIMERIC THERAPEUTIC ANTI-CD-37 ANTIBODY HH1 | 2012 |
|
RU2658438C2 |
| COMPOSITIONS RELATED TO CLOSTRIDIUM DIFFICILE MUTANT TOXIN, AND METHODS OF APPLICATION THEREOF | 2012 |
|
RU2592686C2 |
| VERSIONS OF IL-21 | 2006 |
|
RU2412199C2 |
| SPECIFIC LINKING AGENTS AGAINST B7-H1 | 2010 |
|
RU2571204C2 |
| ANTI-LAG-3 DOSING REGIMENS AND THEIR USE | 2018 |
|
RU2801208C2 |
